Creative BioMart Products & Reviews

A complete set of recombinant interleukins, key signaling molecules of the immune system, for research in immunology, inflammation, cancer, and therapeutic development.

A specialized protein interaction screening service designed to identify interacting partners for membrane proteins, which are typically difficult to study with conventional Y2H.

A powerful technology platform for screening large libraries of antibodies, peptides, or protein domains displayed on phage to identify high-affinity binders against any target.

A diverse collection of proteins engineered for therapeutic use, including cytokines, growth factors, enzymes, and monoclonal antibodies, supporting the development of novel biologic drugs.

Integrated services to rapidly test thousands to millions of compounds, antibodies, or genes for activity against your target protein or cellular assay in an automated format.

A focused set of recombinant immune regulatory proteins, such as PD-1, PD-L1, and CTLA-4, essential for research and drug discovery in cancer immunotherapy and autoimmunity.

A recombinant B-lymphocyte surface antigen, CD19, which is a pivotal target for immunotherapy in B-cell malignancies, including CAR-T cell and antibody-based therapies.

A wide array of recombinant human and animal cytokines, chemokines, and interferons for studying immune responses, inflammation, hematopoiesis, and cell communication.

Recombinant proteins specifically relevant as E3 ligases or target proteins for Proteolysis Targeting Chimeras (PROTACs), enabling the development of this novel targeted protein degradation technology.

A broad selection of recombinant growth factors, such as FGFs, EGF, and VEGF, essential for promoting cell proliferation, survival, and specialization in research and bioprocessing.

Ready-to-use kits providing optimized reagents and protocols for rapid, reliable, and reproducible detection and quantification of specific biological targets or activities.

A portfolio of recombinant immunoglobulins and cell surface proteins serving as critical targets for the development and functional validation of Chimeric Antigen Receptor T-cell (CAR-T) therapies.

A suite of analytical services, including SPR, BLI, and ITC, to quantitatively characterize the binding kinetics, affinity, and thermodynamics of biomolecular interactions.

Recombinant Human Leukocyte Antigen G (HLA-G), a non-classical MHC class I molecule involved in immune tolerance at the maternal-fetal interface and in immune evasion by tumors.

Recombinant TNF superfamily ligands and receptors, pivotal for research into apoptosis, cell survival, inflammation, and immune regulation.

Highly specific and sensitive native or recombinant antigens crucial for the development, calibration, and validation of immunoassays and diagnostic test kits.

Custom chemical conjugation of Polyethylene Glycol (PEG) polymers to proteins to enhance their pharmacokinetic properties, including increased half-life and reduced immunogenicity.

Recombinant Human Fibroblast Growth Factor 2 (Basic FGF), a potent mitogen and morphogen for a wide range of mesoderm and neuroectoderm-derived cells in culture.

Recombinant Human Erythropoietin (EPO), the primary hormone regulating red blood cell production (erythropoiesis), used in research and as a therapeutic for anemia.

Comprehensive analytical services to determine the structural integrity, purity, identity, and post-translational modifications of your protein using state-of-the-art techniques.

Recombinant proteins representing well-validated antigens for Antibody-Drug Conjugates (ADCs), facilitating the screening, characterization, and development of these targeted oncology therapeutics.

A rapid and flexible protein synthesis system that uses cell lysates rather than living cells to produce proteins, ideal for high-throughput expression of toxic or unstable proteins.

Active, stabilized G-Protein Coupled Receptors (GPCRs), prepared in native-like conformations, for high-throughput screening, ligand binding studies, and structure-based drug discovery.

Recombinant Human Programmed Cell Death Protein 1 (PD-1/CD279), a critical immune checkpoint receptor that suppresses T-cell activation and is a major target in cancer immunotherapy.

Recombinant Human B-cell Maturation Antigen (BCMA/TNFRSF17), a TNF receptor superfamily member that is a clinically validated target for multiple myeloma therapies.